Somatic mosaicism is implicated in the etiology of XLAG syndrome

Liliya Rostomyan1, Adrian F Daly2, Bo Yuan2, Frederic Fina3,4, Jean-Hubert Caberg5, Giampaolo Trivellini6, Wouter W de Herder7, Luciana A Naves8, Daniel Metzger9, Thomas Cuny10, Wolfgang Rabl11, Nalini Shah12, Marie-Lise Jaffrain-Rea13, Maria Chiara Zatelli14, Fabio R Fauzii6, Emilie Castermans6, Isabelle Nanni-Metelli8, Maya Lodish9, Ammar Muhammad9, Leonor Palmeira6, Ilaria Potrac1, Giovanna Mantovani15, Sebastian J Noggers1, Marc Klein16, Anne Barlier16,17, Pengfei Liu1, L’Houcine Ouafik4, Vincent Bours5, James R Lupski7,18,19, Constantine A Stratakis6 and Albert Beckers1

Context
X-linked acrogigantism (X-LAG) syndrome is a newly described form of early onset heritable pituitary gigantism caused by microduplications on chromosome Xq26.3 including the GPR101 gene.

Aim
We explored the genomic pathophysiology of XLAG syndrome and studied XLAG, pituitary gigantism, or acromegaly patients for somatic mosaicism of Xq26.3 microduplications that include GPR101.

Methods
Copy number variations (CNVs) at the GPR101 gene were assessed and compared to ZIC3 (nearest protein-coding gene on chromosome X not included in duplications causing XLAG) by droplet digital PCR (ddPCR) in 36 acromegalis (24M; age at diagnosis: 22 - 50 years), 6 acromegaly homogeneous FIPA cases, 22 pituitary gigantism patients, and 20 controls. In 18 XLAG patients (6M - 3 sporadic, 3 familial, and 12 F - 11 sporadic, 1 familial) high-definition array comparative genomic hybridization (HD-aCGH) and breakpoint junction (JCT)-specific ddPCR were performed to characterize Xq26.3 duplications and quantify their level of mosaicism.

Results
On HD-aCGH all XLAG microduplications were unique and included GPR101. All male subjects had a decreased log2 ratio (LR) than expected value of LR=1, suggesting potential mosaicism, whereas there was no evidence of mosaicism in XLAG females. Males as a group had significantly lower LR values compared with female patients. Moreover, sporadically males had lower levels of Xq26.3 duplication mosaicism in blood DNA (range 16.1 - 53.8%) than familial XLAG males (69.1 - 78.5%). These findings were then confirmed using a personalized (JCT)-specific quantification ddPCR and the mosaicism levels obtained with this technique were consistent with the HD-aCGH results. Using a separate ddPCR technique, we studied the feasibility of identifying XLAG cases in acromegaly/gigantism patients’ population by abnormalities in copy number at GPR101 vs. ZIC3. One female gigantism patient was found having increased CNV threshold for GPR101 and was subsequently diagnosed with XLAG microduplication on HD-aCGH.
Conclusions

In this study we demonstrated using a combination of HD-aCGH and novel ddPCR approaches, for the first time, that XLAG syndrome can be caused by somatic mosaicism for duplications at chromosome Xq26.3. Sporadic males but not females with XLAG were found to have variable degrees of somatic mosaicism. Screening for changes in CNV at GPR101 by ddPCR technique may identify a potential XLAG case among pituitary gigantism population.

1 Department of Endocrinology, Centre Hospitalier Universitaire de Liege, University of Liege, Liege, Belgium
2 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
3 Assistance Publique Hôpitaux de Marseille (AP-HM), Hôpital Nord, Service de Transfert d’Oncologie Biologique, Marseille, France
4 Laboratoire de Biologie Médicale, and Aix Marseille Université, Inserm, CRO2 UMR 5911, Marseille, France
5 Department of Human Genetics, Centre Hospitalier Universitaire de Liege, University of Liege, Liege, Belgium
6 Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, Maryland, USA
7 Section of Endocrinology, Department of Medicine, Erasmus University Medical Center Rotterdam and Pituitary Center Rotterdam, Rotterdam, The Netherlands
8 Department of Endocrinology, University of Brasilia, Brasilia, Brazil
9 Endocrinology and Diabetes Unit, BC Children’s Hospital, Vancouver, British Columbia, Canada
10 Department of Endocrinology, University Hospital, Nancy, France
11 Kinderklinik, Technische Universität München, Munich, Germany
12 Department of Endocrinology, KEM Hospital, Mumbai, India
13 Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila and Neuromed Institute, IRCCS, Pozzilli, Italy
14 Section of Endocrinology, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
15 Endocrinology and Diabetology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy
16 Laboratory of Molecular Biology, APHM, Hospital la Conception, Aix Marseille Universite, Marseilles, France
17 CNRS, CRN2M UMR 7286, Marseille, France
18 Department of Pediatrics, Baylor College of Medicine and Texas Children’s Hospital, Houston and Texas, USA
19 Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas, USA